Treatment of opioid addiction using fibroblasts and products thereof

    公开(公告)号:US12133870B2

    公开(公告)日:2024-11-05

    申请号:US16822746

    申请日:2020-03-18

    Applicant: SPINALCYTE LLC

    Abstract: Disclosed are methods and compositions comprising fibroblasts and/or products derived thereof for the inhibition and/or treatment of addiction of any kind, such as opioid addiction. In some embodiments, methods comprise treating a patient addicted to opioids by administering a fibroblast population at a concentration sufficient for suppression of addiction-associated brain damage. In some embodiments, the fibroblasts express CD31 and/or CD73 markers. In some embodiments, fibroblasts are used to endow neuronal regeneration in order to overcome changes in the brain associated with addiction. Some embodiments relate to the stimulation of hippocampal regeneration subsequent to addiction induced damage.

    LYMPHANGIOGENESIS PROMOTING FACTOR-EXPRESSING FIBROBLAST, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME

    公开(公告)号:US20240148795A1

    公开(公告)日:2024-05-09

    申请号:US18548803

    申请日:2022-03-03

    Applicant: METCELA INC.

    Inventor: Takahiro IWAMIYA

    CPC classification number: A61K35/33 A61P11/00 A61P43/00

    Abstract: A fibroblast highly expressing ADM and/or HHEX has been found as a cell having lymphangiogenesis ability, and a procedure for treating fibrosis, a procedure for ameliorating a condition of lymphangiogenesis ability reduced, and procedures for modulating homeostasis of a tissue fluid, transport of lipid and/or vitamin, and immunological surveillance, and for treating organ failure, by use of a pharmaceutical composition including the fibroblast, have been found. In addition, it has been found that an adult-derived fibroblast highly expressing ADM and increasing expression of VCAM-1 is obtained by culturing a human fibroblast with a medium to which TNF-α and IL-4 are added and it has been found that a fibroblast highly expressing ADM is provided, and a procedure for treating a pulmonary disease by use of the fibroblast has been found.

    Concurrent activation of regenerative and tolerogenic processes by fibroblast-based compositions for the treatment of multiple sclerosis

    公开(公告)号:US11878037B2

    公开(公告)日:2024-01-23

    申请号:US16887720

    申请日:2020-05-29

    Applicant: Figene, LLC

    CPC classification number: A61K35/33 C12N5/0656 C12N2501/22 C12N2501/26

    Abstract: Described are means, methods, and compositions useful for treatment of multiple sclerosis through the utilization of fibroblasts and/or derivatives thereof to concurrently stimulate regenerative processes while inducing a protolerogenic immune modulatory program. In certain embodiments, fibroblasts are selected for the concurrent properties of immune modulation and regeneration by enrichment for CD73 expressing fibroblasts. In particular embodiments, stimulation of regeneration implies activation of endogenous neural progenitor cells. In some embodiments, stimulation of regeneration implies induction of remyelination. The utilization of fibroblasts as a superior source for immune modulation, prevention of immune mediated pathology, and activation of T regulatory cells is provided within the context of multiple sclerosis.

Patent Agency Ranking